England to rollout world-first seven-minute cancer treatment jab
Reuters
Published Aug 29, 2023 21:58
Updated Aug 29, 2023 23:10
(Reuters) - Britain's state-run national health service will be the first in the world to offer an injection that treats cancer to hundreds of patients in England which could cut treatment times by up to three quarters.
Following approval from the Medicines and Healthcare products Regulatory Agency (MHRA), NHS England said on Tuesday hundreds of eligible patients treated with the immunotherapy, atezolizumab, were set to have "under the skin" injection, which will free up more time for cancer teams.
"This approval will not only allow us to deliver convenient and faster care for our patients, but will enable our teams to treat more patients throughout the day," Dr Alexander Martin, a consultant oncologist at West Suffolk NHS Foundation Trust said.
NHS England said atezolizumab, also known as Tecentriq, is usually given to patients intravenously, directly into their veins via a drip, which could often take around 30 minutes or up to an hour for some patients when it can be difficult to access a vein.
"It takes approximately seven minutes, compared with 30 to 60 minutes for the current method of an intravenous infusion," Marius Scholtz, Medical Director at Roche Products Limited said.
Atezolizumab - made by Genentech, a Roche company - is an immunotherapy drug that empowers a patient's own immune system to seek and destroy cancerous cells. The treatment is currently offered by transfusion to NHS patients with a range of cancers, including lung, breast, liver and bladder.
NHS England said it expected the majority of around 3,600 patients starting the treatment of atezolizumab every year in England to switch onto the time-saving injection.
But added that patients receiving intravenous chemotherapy in combination with atezolizumab may remain on the transfusion.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.